Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B
Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B
复制标题
DOI：
10.1111/liv.13641
复制
发表时间：
2018-02-01
影响因子：
6.7
通讯作者：
Esteban, Rafael
中科院分区：
文献类型：
--
作者：
Buti, Maria;Riveiro-Barciela, Mar;Esteban, Rafael
用核苷（酸）类似物长期治疗慢性B型肝炎（CH B）通常是实现持久病毒抑制所必需的。因此，目前的指南推荐具有最佳耐药性的最有效药物。恩替卡韦（ETV）、富马酸替诺福韦酯（TDF）和替诺福韦艾拉酚胺（TAF）是CHB的一线单药治疗。所有这些药物在抑制病毒复制方面都非常有效，但安全性略有不同。本综述概述了自ETV和TDF首次获批用于治疗慢性肝炎以来10年来的长期疗效和安全性数据，以及TAF治疗CHB患者的最新数据。
Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first-line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long-term efficacy and safety data that have become available over the 10years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.